FindTrial
Sign In

Predictive capability of sarcopenia in patients treated with immune checkpoint inhibitors. A meta-analysis

Predictive capability of sarcopenia in patients treated with immune checkpoint inhibitors. A meta-analysis - effect of sarcopenia on cancer immunotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000042621
Enrollment
Unknown
Registered
2020-12-03
Start date
2020-12-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer patients treated with immune checkpoint inhibitors

Interventions

None listed

Sponsors

Kansai medical hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1,articles regarding cancer patients treated with immune checkpoint inhibitors 2,presence of sarcopenia was evaluated before the start of immunotherapy 3, hazard ratios or odds ratio for overall survival, progression-free survival, objective response rate, disease control rate, immune related toxicity are described or can be estimated.

Exclusion criteria

Exclusion criteria: review, case report, animal study languages other than English or Japanese

Design outcomes

Primary

MeasureTime frame
hazard ratio for progression free survival hazard ratio for overall survival odds ratio for objective response odds ratio for disease control odds ratio for toxicity—

Countries

Japan

Contacts

Public Contactyukinori takenaka

Kansai medical hospital department of otolaryngology

ytakenaka@ent.med.osaka-u.ac.jp+81668361199

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026